IP36-22: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience

IP36-22: Perioperative and Oncologic Outcomes of Consolidative Surgery for Advanced Urothelial Carcinoma Following Induction Enfortumab Vedotin and Pembrolizumab: A Multicenter Experience

Saturday, May 16, 2026 9:30 AM to 11:30 AM · 1 hr. 59 min. (America/New_York)
147B
Abstract

Registered attendees

Matthew Mcleay
Matthew Mcleay
Urologic Oncology FellowMayo Clinic

Log in

See all the content and easy-to-use features by logging in or registering!